Dentsply Sirona Inc is a global leader in the dental industry, specializing in the manufacturing and distribution of a wide range of dental products and technologies. The company provides innovative solutions for dental professionals, including equipment, instruments, and materials used in various dental procedures, such as restorative, preventive, and orthodontic care. Dentsply Sirona focuses on improving patient outcomes through advancements in dental technology, offering products that enhance treatment efficiency and effectiveness. By catering to dental professionals worldwide, the company plays a pivotal role in enhancing oral health and clinical practice standards. Read More
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.
Dental products company Dentsply Sirona (NASDAQ:XRAY) announced better-than-expected revenue in Q1 CY2025, but sales fell by 7.8% year on year to $879 million. The company’s full-year revenue guidance of $3.65 billion at the midpoint came in 2.2% above analysts’ estimates. Its non-GAAP profit of $0.43 per share was 43.3% above analysts’ consensus estimates.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Let’s dig into the relative performance of Dentsply Sirona (NASDAQ:XRAY) and its peers as we unravel the now-completed Q4 dental equipment & technology earnings season.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Envista (NYSE:NVST) and the best and worst performers in the dental equipment & technology industry.
Dentsply Sirona’s stock price has taken a beating over the past six months, shedding 46.9% of its value and falling to $12.92 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Let’s dig into the relative performance of Align Technology (NASDAQ:ALGN) and its peers as we unravel the now-completed Q4 dental equipment & technology earnings season.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Henry Schein (NASDAQ:HSIC) and the best and worst performers in the dental equipment & technology industry.
Dental products company Dentsply Sirona (NASDAQ:XRAY) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 10.6% year on year to $905 million. The company’s full-year revenue guidance of $3.55 billion at the midpoint came in 5% below analysts’ estimates. Its non-GAAP profit of $0.26 per share was 40.1% below analysts’ consensus estimates.
